menu search

In a push to limit use of glucocorticoids, us and eu5 rheumatologists are increasingly turning to gsk’s benlysta and astrazeneca’s saphnelo for the treatment of moderate-to-severe systemic lupus eryth

Despite overall biologic growth in both geographies, use of advanced systemic treatments in the US outpaces the EU5. Exton, Pennsylvania, Oct. 04, 202...

October 4, 2023, 7:00 am


Search within

Pages Search Results: